drugset / Trial / NCT06033703

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

NCT06033703

Phase 1/2 Recruiting 48 enrolled Massachusetts Eye and Ear Infirmary
RandomizedParallel-groupOpen-labelPrevention

Summary

This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.

Timeline

Start
2025-01-14
Primary completion
2026-09
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Topical